Clinical Protocol to Investigate the Efficacy of Amlexanox vs. Placebo for Treatment of Glucose and Lipid Abnormalities in Obese Type 2 Diabetics
Phase of Trial: Phase II
Latest Information Update: 10 Jun 2017
At a glance
- Drugs Amlexanox (Primary)
- Indications Non-alcoholic fatty liver disease; Obesity; Type 2 diabetes mellitus
- Focus Biomarker; Pharmacodynamics
- 10 Jun 2017 Biomarkers information updated
- 03 Feb 2017 Status changed from active, no longer recruiting to completed.
- 22 Aug 2016 Status changed from recruiting to active, no longer recruiting.